GlassScriptPhysician profile
Alan H Resnick
NPI 1548244825
$9,491.78
in general payments reported to CMS, 2019-2025
24 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,864 · 2020: $685 · 2021: $2,527 · 2022: $495 · 2023: $639 · 2024: $1,053 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,824 · Education: $95.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.64 |
| Education | $95.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,766.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,677.80 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Shire North American Group INC | $1,465.76 | 2019 | |
| Glaxosmithkline, LLC. | $1,389.13 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $933.39 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $586.51 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.70 | 2019-2024 | Spiriva Respimat |
| Alk-Abello, INC | $249.53 | 2019-2020 | |
| Genentech USA, INC. | $204.98 | 2019-2025 | Xolair |
| Csl Behring | $181.50 | 2019-2025 | Hizentra |
| Covis Pharma Gmbh | $129.22 | 2019-2022 | |
| Octapharma USA, INC. | $110.76 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.33 | 2020-2025 | Glassia |
| Hikma Pharmaceuticals USA | $95.76 | 2024-2025 | Ryaltris |
| Pfizer INC. | $82.19 | 2019-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $80.25 | 2019-2021 | |
| Pharming Healthcare, INC. | $40.23 | 2022-2025 | Ruconest |
| Amgen INC. | $38.07 | 2021-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $33.43 | 2019-2025 | |
| Lilly USA, LLC | $21.38 | 2025 | Ebglyss |
| Biocryst US Sales Co., LLC | $17.42 | 2023 | Orladeyo |
| Merck Sharp & Dohme LLC | $13.43 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.96 | 2021 | |
| Optinose US, INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Resnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.